ARTICLE | Top Story
Negative Actelion/DNA Phase III data
April 20, 2001 7:00 AM UTC
Actelion (SWX:ATLN) and partner Genentech (DNA) said preliminary data from their 675-patient RITZ-1 (randomized intravenous Tezosentan) Phase III study showed Veletri tezosentan endothelin receptor an...